A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE).

NG-350A - PsiOxus

enadenotucirev (ColoAd1) - PsiOxus

https://iplanner.asco.org/am2019/#/session/13719

Aung Naing; Ecaterina Elena Ileana Dumbrava; Ravi Murthy; Funda Meric-Bernstam; Andrew Fox; David Krige; Jo Carter; Brian Champion; Paul Cockle; Barbara Koetz; Hilary McElwaine-Johnn

Jun 6, 2019